Legend Biotech Expands U.S. Innovation Footprint With State-of-the-Art Philadelphia Research Facility; To Advance Next-Generation Cell Therapies

Legend Biotech Corporation has officially opened its new 31,000-square-foot R&D facility in Philadelphia, marking a significant expansion of its U.S. research footprint. The site, located at 2300 Market Street, is fully operational and equipped with advanced labs and collaborative areas designed to accelerate development of the company’s next-generation cell therapy programs.

“This new facility marks an exciting milestone for Legend Biotech as we continue to invest in our future and strengthen our leadership in cell therapy innovation,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “We are proud to officially open our doors in Philadelphia, a world-class hub for life sciences, where we can attract top-tier talent, collaborate with premier research institutions, and advance our mission to bring transformative therapies to patients.”

This new Philadelphia center strengthens Legend’s U.S. presence, which already includes more than 1,400 employees nationwide and established R&D operations in Piscataway, New Jersey. Approximately 55 full-time employees will staff the new facility, complementing the company’s headquarters in Somerset, N.J., and manufacturing sites in Raritan and Morris Plains. The ribbon-cutting ceremony brought together local officials, academic collaborators, patient advocacy groups, and members of the regional biotech community.

“The opening of our new facility represents an exciting new chapter for our research organization,” said Guowei Fang, Ph.D., President of Research and Development at Legend Biotech. “Our Philadelphia team will play a critical role in advancing our sustainable pipeline of innovative cell therapies, while strengthening collaborations within one of the nation’s most dynamic biotech ecosystems.”

“Philadelphia continues to be a magnet for innovation and scientific excellence,” said Chris Molineaux, CEO of Life Sciences Pennsylvania. “We are thrilled to welcome Legend Biotech to our city’s thriving life sciences community. Their investment brings high-quality jobs, research opportunities, and further reinforces Philadelphia’s growing reputation as a global leader in healthcare innovation.”

Legend Biotech remains a global leader in cell therapy and the largest standalone company in the space. It is best known for CARVYKTI®, its groundbreaking CAR-T therapy for relapsed or refractory multiple myeloma, developed in partnership with Johnson & Johnson. More than 9,000 patients across 44 states have received the therapy at 132 treatment centers. With its expanding infrastructure, Legend aims to enhance CARVYKTI access while advancing a robust pipeline of innovative cell therapy modalities.

“Legend Biotech’s decision to expand its R&D footprint in Philadelphia reflects the strength and momentum of our city’s life sciences ecosystem,” said Dr. Rebecca L. Grant, Director of Life Sciences & Innovation for the City of Philadelphia’s Department of Commerce. “Philadelphia is home to world-class scientific talent and research institutions, and we are proud to welcome an organization committed to pioneering therapies that change patient lives. We look forward to supporting Legend Biotech as they grow here and contribute to the continued advancement of cell and gene therapy innovation in our city.”